FIELD: medicine.
SUBSTANCE: inventions relate to immunotherapy for CD38-associated cancer. A method and unit dosage form are provided for treating relapsed/refractory multiple myeloma (RRMM) in a subject. The subject is administered subcutaneously isolated human anti-CD38 antibody at a dose of 45 to 1,800 mg, where the dose is a once-weekly dose. The anti-CD38 antibody contains CDR1-6 having the following amino acid sequences SEQ ID NO: 3-8, respectively. The unit dosage form contains from 45 to 1,800 mg of isolated antibody having a heavy chain variable region containing the following SEQ ID NO: 9, and a light chain variable region containing the following SEQ ID NO: 10. The isolated antibody binds to CD38 and does not bind to human red blood cells. The volume of the unit dosage form is 2.5 ml or less.
EFFECT: invention provides effective treatment for RRMM, including in patients with late stage of RRMM preventing side effects.
16 cl, 26 dwg, 11 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBCUTANEOUS INJECTION OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2782950C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| METHODS AND MATERIALS FOR ASSESSMENT OF RESPONSE TO THERAPY AGAINST PLASMA-BLASTS AND PLASMA CELLS | 2017 |
|
RU2787629C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
